About in8bio inc - INAB
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
INAB At a Glance
IN8bio, Inc.
350 5th Avenue
New York, New York 10118
| Phone | 1-646-600-6438 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -19,440,000.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.829 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.811 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.198 |
INAB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,143,529.412 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INAB Liquidity
| Current Ratio | 8.82 |
| Quick Ratio | 8.82 |
| Cash Ratio | 8.571 |
INAB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -71.643 |
| Return on Equity | -92.492 |
| Return on Total Capital | -64.074 |
| Return on Invested Capital | -82.755 |
INAB Capital Structure
| Total Debt to Total Equity | 10.095 |
| Total Debt to Total Capital | 9.169 |
| Total Debt to Total Assets | 8.618 |
| Long-Term Debt to Equity | 5.672 |
| Long-Term Debt to Total Capital | 5.152 |